BREAKING: Bayer shares fall 10 percent after Monsanto’s Roundup cancer trial

By Erin Elizabeth

Last week when I shared that Monsanto had been ordered to pay $289.2 million to former school groundskeeper Dewayne Johnson, currently dying of cancer (due to the Roundup he used) I suggested that perhaps this trial- the first of thousands– was the first crack in their wall. And I may have been right.

RELATED STORY: https://www.healthnutnews.com/bayer-monsanto-a-match-made-in-hell/

This morning, Bayer (BAYGn.DE) shares plunged more than 10 percent likely in response to Friday’s judgment. While Monsanto plans to appeal the verdict, I don’t think even they can stop this train. Now that emails have been leaked and the science has been done showing the chemical is not safe, the end feels near. (And Bayer just shelled out how much money to buy up Monsanto?)

-Today, Bayer shares were down 11 percent at 83.04 euros at 0915 GMT, the worst performing stock on the Stoxx Europe 600 index.

-Glyphosate-exposed stocks also plunged in Asia and particularly in Australia where a withering drought has already hit herbicide sales.

-Australian chemical maker Nufarm Ltd (NUF.AX), which Macquarie Bank analysts estimate earns about a fifth of its revenue from glyphosate-based products, plunged almost 17 percent to a more than two-year low.

-And its top shareholder, Japan’s Sumitomo Chemical Co Ltd (4005.T), shed 3 percent, while Australian rural services firm Elders Ltd (ELD.AX), which retails herbicides, fell 11 percent to a nine-month low.

Read more -------> https://www.healthnutnews.com/breaking-bayer-shares-fall-10-percent-after-monsantos-roundup-cancer-trial/